Navigation Links
Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
Date:8/22/2011

SEATTLE, Aug. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use ("CHMP") in regards to CTI's Marketing Authorization Application for pixantrone (the "MAA") to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). With this submission, CTI expects to receive a CHMP opinion regarding approvability of pixantrone during the first quarter of 2012.

"We have now submitted answers to the CHMP list of questions moving pixantrone a step closer to potential approval," said James A. Bianco, CEO of CTI. "Following an encouraging meeting with the EMA earlier this year and based on recommendations from the rapporteurs, we requested and received an extension to answer all the EMA's questions in the Day 120 letter. We believe we have been able to provide quality responses to each of the questions posed and we expect this positions us to receive an opinion by the early next year.  If the opinion is positive, we expect that the commercial launch of pixantrone in Europe could occur as early as the first half of 2012."

In the United States, CTI expects to resubmit its New Drug Application for pixantrone (the "NDA") to the U.S. Food and Drug Administration (the "FDA") during the fourth quarter of 2011 and the FDA has indicated the NDA would receive a six month review resulting in a decision on approval of the NDA by the FDA in the United States as early as April 2012.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines -- rather than intercalation with DNA -- pixantrone alkylates DNA -- f
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
2. Echo Therapeutics Announces Second Quarter 2011 Financial Results
3. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
4. Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription
5. Echo Therapeutics Unveils Symphony tCGM Demonstration Video
6. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
7. Echo Therapeutics Announces Multiple Patents and Trademark Grants
8. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
9. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
10. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
11. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 The scientific team of a ... of the leading academics in the field of aging Prof. ... in life extension for model animals - 10 fold for ... and age-related diseases, primarily, around the stability and stress resistance ... published as "Stability analysis of a model gene network links ...
(Date:8/28/2015)... FARUM, Denmark and ATLANTA ... July 31, 2015 the US Food and Drug Administration (FDA) ... Major Depressive Disorder in adult patients who have failed to ... episode. TMS is a non-invasive technique for stimulating neural tissue ... from Major Depressive Disorder. The procedure has been proven safe ...
(Date:8/28/2015)... de agosto de 2015   Royal Philips ... en el  Congreso de la ESC de 2015 ... y novedosas, entre ellas HeartModel A.I.  , EchoNavigator ... y la tecnología con los protocolos de atención ... tratamientos y permitir atención en el hogar. ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
(Date:8/29/2015)... ... 29, 2015 , ... It can be uncomfortable to wear ... and sweat. "In order to prevent these problems, I conceived of my design," ... MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It improves comfort for ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder ... mission is to increase acceptance of the chiropractic field in the military. All too ... them. Although Chiropractic was made available to the VA program over a decade ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Next weekend is ... summer (which astronomically, officially ends on September 22nd this year). For IT security personnel, ... hangovers linger on which could prove far more costly than a simple headache. , ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire ... heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... school seniors drink because they want to experiment with alcohol, ... it helps them relax. A new study finds that a ... for drinking, but they also drink to get away from ... with multiple reasons to drink, including reasons related to coping ...
... life span and heat tolerance in ... ... the chemical,that gives rotten eggs their sulfurous stench -- and the same ... mice into a state of reversible metabolic hibernation -- has,now been shown ...
... Best Drugs for 35 Conditions, YONKERS, N.Y., ... between doctors and patients, especially,when it comes to ... the,January issue of Consumer Reports, in which CR ... about drugs for 35 conditions including,Alzheimer,s disease, heart ...
... Words, Contains Candidates, Quotes on Health Care,Financial Security ... out from the,first caucus in Iowa, Divided We ... information they need come Election Day to decide ... and financial security., (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ...
... Coherent, Inc.,(Nasdaq: COHR ) today announced that ... Board of Directors of The Nasdaq Stock Market ("Nasdaq") ... past due periodic reports,for the year ended September 30, ... the Securities Exchange Commission ("SEC") in order to regain,compliance ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a ... treatment of venous reflux disease, today,announced the appointment ... & Development., Mr. Kamdar joins VNUS with ... medical device industry. Most recently, he served as,Senior ...
Cached Medicine News:Health News:Why do high school seniors drink? 2Health News:Could Hydrogen Sulfide Hold the Key to A Long Life? 2Health News:Could Hydrogen Sulfide Hold the Key to A Long Life? 3Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 2Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 3Health News:Divided We Fail Presidential Side-by-Side to Reach 23M+ AARP Members 2Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 2Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 3Health News:VNUS Medical Technologies Appoints Kirti Kamdar as Senior Vice President of Research & Development 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: